Parenteral administration of the serotonin-1 agonist eltoprazine (0.0625 to 4.0 mglkg [0.0002 to 0.016 mmollkgJ) in freely moving cats produced significant suppression of electrophysiologic rapid eye movement (REM) sleep signs, ponto-geniculo-occipital (PGG) activity, and REM sleep behavior. The virtual total suppression of REM sleep (0.4%, 4.0 mglkg) and PGG wave activity (2 to 4 mglkg) in exchange for increasing amounts of non-REM (NREM) slow-wave sleep was a dose-dependent function of the amount of eltoprazine KEY WORDS: REM sleep; PGG waves; Serotonin; Eltoprazine Despite the large number of studies implicating sero tonin (5-HT) in the modulation of behavioral state, its exact role in the regulation of sleep and waking remains unclear. Pharmacological studies designed to elucidate the mechanism by which 5-HT neurotransmission aff ects behavioral state have reported paradoxical or contradictory results. While the listing of multiple 5-HT receptor subtypes (Glennon 1986; Peroutka 1988) has elucidated many of the pharmacological properties of ser otonin and underscores the complexity of its modula tory influences, this research has failed to provide a detailed understanding of behavioral state control and administered. Wakefulness was unaffected by eltoprazine regardless of dose. Concurrent with this dose-dependent suppression of REM was a dose-dependent increase in electroencephalographic synchrony and mean electromyographic amplitude. Since eltoprazine was found to shift the balance between REM and NREM sleep but did not change the balance between sleep and waking, it is a potentially useful tool for the investigation of serotonergic-cholinergic interaction.
Despite the large number of studies implicating sero tonin (5-HT) in the modulation of behavioral state, its exact role in the regulation of sleep and waking remains unclear. Pharmacological studies designed to elucidate the mechanism by which 5-HT neurotransmission aff ects behavioral state have reported paradoxical or contradictory results. While the listing of multiple 5-HT receptor subtypes (Glennon 1986; Peroutka 1988) has elucidated many of the pharmacological properties of ser otonin and underscores the complexity of its modula tory influences, this research has failed to provide a detailed understanding of behavioral state control and administered. Wakefulness was unaffected by eltoprazine regardless of dose. Concurrent with this dose-dependent suppression of REM was a dose-dependent increase in electroencephalographic synchrony and mean electromyographic amplitude. Since eltoprazine was found to shift the balance between REM and NREM sleep but did not change the balance between sleep and waking, it is a potentially useful tool for the investigation of serotonergic-cholinergic interaction.
lNeuropsychopharmacology 8:7-13, 1993J neurophysiological phenomena. One reason for this failure is that surprisingly few studies have focused on how administration of receptor-specifIc 5-HT agonists affects sleep, particularly rapid eye movement (REM) sleep.
We have previously observed suppression of REM sleep by the parenteral administration of the 5-HTl agonist eltoprazine (Quattrochi et al. 1990 ) and docu mented the REM rebound that followed discontinua tion of the drug. These findings support the hypothe sis that REM sleep is under the inhibitory control of serotonin (Hobson and Steriade 1986) . We now dem onstrate that the suppression of REM sleep is dose de pendent and show that the dose-response properties of one relatively specifIc REM sleep sign, ponto geniculo-occipital (PGO) waves, are quantitatively sen sitive to eltoprazine.
PGO waves are of particular interest because they are highly specifIc phenomena of REM sleep. Early studies by Jouvet (1969) , Delorme et al. (1965), and De ment et al. (1973) indicated that PGO activity was sus ceptible to serotonergic inhibition; successive studies have reemphasized this association. The limitation of these studies is that they used drugs that influenced serotonergic neurons indirectly or nonspeciftcally. PGO waves are now known to be generated by PGO burst cells (Sakai 1980 ) located within the region of the cholinergic/peribrachial pontine tegmentum (Steriade et al. 1990a) , and continuous PGO wave activity inde pendent of REM has been described by Vivaldi et al. (1980) following microinjection of the cholinergic agonist carbachol into this peribrachial region. In our study, we observed a signiftcant dose-dependent sup pression of PGO activity during eltoprazine adminis tration. This fInding supports the hypothesis that the c� ? linergic/PGO burst cell network is particularly sen sItIve to serotonergic inhibitory control.
Eltoprazine is a recently developed phenylpipera zine derivative classifIed as a selective 5-HTI ligand (Raghoebar et al. 1990 ). Neurochemical studies provide evidence that the pharmacological actions of eltopra zine in vivo are attributable to interaction with the 5-HT system via specifIc agonist action on 5-HT 1A and 5-HT 1B receptors (Raghoebar et al. 1990) . We now report the results of a dose-response study of the role of eltopra zine in controlling sleep. We demonstrate that the elec trophysiological features of sleep are differentially affected by eltoprazine and that overall suppression of REM in exchange for increasing amounts of non-REM (NREM) slow-wave (S) sleep is a dose-related function of the amount of eltoprazine administered. The dose response profIle of eltoprazine that we have established allows us to clarify and more confIdently interpret its ph � acological effects, since they indicate that the sup pre � slon of REM sleep and PGO activity are directly attnbutable to the serotonergic agonist action of the drug. The effects of eltoprazine on a known choliner gic REM sleep state may contribute to the behavioral profIle of eltoprazine.
METHODS

Animal Preparation
Stereotaxic implantation of chronic recording electrodes was performed with pentobarbital sodium (35 mg/kg) anesthesia administered IP to four adult male cats weigh�ng 3.5 to 5.0 kg. Placement of insulated tung sten WIre electrodes permitted recording of cortical elec troencephalograms (EEG), nuchal electromyograms (EMG), posterior orbital electrooculograms and bilateral lateral geniculate bodies for measurement of PGO wave activity. These procedures are described in detail else where (Quattrochi et al. 1989) . Animals were allowed to recover for 10 to 14 days after surgery before begin ning control recordings. NEUROPSYCHOPHARMACOLOGY 1993-VOL. 8, NO.1 
Pharmacological Protocol
E�topra � ine (1-[2,3-dihydro-1,4-benzodioxin-5-yl] plparazme, DU28853, Duphar B.V.) is reported to dem onstrate high affinity to 5-HTIA (Ki = 40 nmollL) and 5-HTIB (Ki = 52 nmollL) receptor subtypes (Raghoebar et al. 1990 ). Affinity toward other neurotransmitter receptors such as 5-HT2,3, Ql,2, Ih,2, Dl,2, and Ml,2,3 is si � iftcantly lower (Ki > 400 nmollL). A semilogarith rruc dosage schedule was used. All injections were per formed IP in a total injection volume of 2 cc sterile sa line and administered each day at 11:00 A.M. Control injections consisted of saline. Eltoprazine was ad ministered on the day after control recordings were per formed; a washout period of fIve days followed. The dose-response curve was generated by the following dose amounts of eltoprazine: 0.0625, 0.125, 0.25, 0.5, 1.0, 2.0, and 4.0 mg/kg (0.0002, 0.0005, 0.001, 0.002, 0.004, 0.008, and 0.016 mmollkg). Each dose was ad ministered among cats in a balanced order (low to high [n = 2]; high to low [n = 2]).
Recording of Behavioral State
Electroencephalogram recordings were performed con tinuously for 22 hours on unrestrained cats using Grass model 810 and model 6 electroencephalographs. All trials were conducted in a recording cage (4 x 2 x 2 feet) under constant illumination. Food and water were provided ad lib. During the two unrecorded hours (9:00 A.M. to 11:00 A.M.) each day, cats were kept awake while being fed, exercised, and cared for in an adjacent ani mal room.
Data Acquisition
Polygraphic data were collected by our automated data acquisition system (DAS) as previously described (Mamelak et al. 1991) . Four wavebands were moni tored: delta (1 to 4 Hz), spindle (5 to 14 Hz burst of 3 or more waves), PGO (4 to 14 Hz, monophasic) and EMG (amplitude units). Using the DAS, we acquired continuous quantitative measures of electrographic parameters for each control and dose condition in all four cats and stored these data for quantitative analysis.
Quantitative Analysis of Waveband Counts
Behavioral state was determined by computer scoring all sleep recordings in IS-second bins using a previously described neural network program (Mamelak et al. 1991) and spot checking hand scoring of selected records. Waveband counts were quantifted and ana l � zed by dose and cat. Three wavebands were quan tifIed-delta, PGO, and EMG amplitude. Since both be-havioral state percentage and waveband parameters demonstrated similar trends for all cats, we restricted our detailed quantitative analysis of waveband counts to one cat. Data from counts in consecutive 1 minute epochs were summed into hourly count totals and then subjected to multivariate analysis of variance. Dose and hour effects were investigated. Post hoc Scheffe and Bonferroni t tests (p < 0.05) were performed to deter mine if variability between condition was attributable to intrinsic variation among cats. All statistical analy ses were performed on a mainframe computer using SAS statistical analysis software (SAS Institute).
RESULTS
Results were compiled from a total of 56 IP injections in cats. Table 1 presents mean values of all behavioral state parameters by dose obtained from 28 eltoprazine and 28 saline injections.
Behavioral State Changes
Total percent of time per 22-hour recording period spent in REM (REM%) decreased in a dose-dependent man ner from a control mean of 14.4 ± 0.4% to a mean of 0.4 ± 0.4% at 4 mg/kg eltoprazine (F = 19.11, p< 0.001). Figure 1A illustrates this dose-related decrease in REM%. The REM% did not vary signifIcantly among cats (F = 1.5, P > 0.20).
Rapid eye movement latency showed a dose dependent increase from a control mean of 62.2 ± 5.0 minutes to a 4.0-mg/kg dose mean of over 22 hours (Fig. IB) . This increase in REM latency was markedly dose dependent and signifIcant (F = 311.17, P < 0.001), and did not vary signifIcantly among cats (F = 0.03, P > 0.5). The dose-dependent lengthening of REM latency in versely parallels the decrease in REM%.
Conversely, tota l time spent in S sleep (S%) showed a dose-dependent increase from a control value of 45.7 ± 2.1% to a mean of 58.7 ± 8.5% at a dose of 4 mg/kg Dose-Related Suppression of REM by Eltoprazine 9 eltoprazine (F = 15.20, P < 0.001; Fig. 1C ). However, this dose-related increase in S% varied by cat (F = 22.42, P < 0.001); most of the variability was shown by one cat, which also diff ered in total time spent awake (W%).
Total time awake was the only behavioral state pa rameter that did not vary by dose. Mean W% under control conditions was 37.8 ± 2.2% and at the 4.0-mg/kg dose was 40.9 ± 8.1%, with no signifIcant variation with dose demonstrated (F = 0.08, P > 0.5; Fig. 10 ). This parameter varied by cat (F = 19.35, P < 0.001), with vari ability confrrmed to be attributable to one cat having a lower W% and correspondingly higher S% than the other cats. Despite these intercat differences in W% and S%, mean values of W% were found to be unchanged regardless of dose for each cat (p > 0.05). Table 2 summarizes the polygraphic parameters mea sured by the computer-based DAS and compared for each dose. The number of PGa waves counted by DAS was observed to be a markedly dose-dependent elec trographic feature of behavioral state (F = 127.53, P < 0.001), ranging from a control value of 968 ± 49 counts per hour to a mean of 19 ± 7 at 4 mg/kg eltoprazine (Fig. 2, top) . PGa wave counts were not observed to be signifIcantly diff erent by hour (F = 1.21, P > 0.25).
Electrographic Waveband Changes
A dose-dependent increase in delta wave counts was observed at the highest dose (4 mg/kg eltoprazine) with a mean of 4465 ± 207 counts per hour compared with a control value of 2345 ± 74 (F = 342.73, P < 0.001; Fig. 2, middle) . Delta wave counts were also shown to be signincantlydifferent by hour (F = 11.39, p< 0.001). However, a signifIcant difference in Fvalues confrrmed that mean variability was attributable to dose (F = 342.73). No statistically signincant increase in delta wave counts was found at doses less than 4 mg/kg el toprazine.
Mean EMG amplitude also increased with increas ing doses of eltoprazine from a control value of 1858 . (58) 568 (78) 654 (66) 422 (65) 300 (49) 18 (7) 19 (7) Delta 2345 (74) 1714 (124) 1928 (134) 2008 (127) 2191 (214) 2342 (265) 3062 (256) 4465 (207) EMG 1858 (237) 2791 (224) 2515 (259) 2310 (266) 3035 (304) 3230 (327) 4216 (397) 5793 (475) Values expressed as mean (SEM) for counts/hr (PGO, delta) and amplitude units/hr (EMG).
± 237 amplitude units to a mean of 5793 ± 475 at 4 mg/kg eltoprazine (F = 146.29, P < 0.001; Fig. 2 , bot tom). As with delta wave activity, this effect on EMG amplitude varied signmcantly by hour (F = 3.34, P < 0.001), with most of the variability attributable to dose (F = 146.29).
DISCUSSION
The purpose of this study was to test the hypothesis that the 5-HT 1 agonist eltoprazine demonstrates dose dependent effects on REM sleep and REM sleep elec trographic parameters. Our hypothesis was based on observations in which eltoprazine administered over fIVe consecutive days totally suppressed REM sleep (Quattrochi et al. 1990) , while total sleep time remained unchanged from control levels . Our data demonstrate that peripheral administration of eltoprazine suppresses REM sleep in a dose-dependent manner, with virtu ally total suppression of REM (0.4%) at the highest dose (4 mg/kg). Concurrent with this dose-dependent sup pression of REM and PGO wave activity is a dose dependent increase in S sleep, EEG synchrony, and mean EMG amplitude. No dose relationship was evi dent with W%.
Our interpretation of these results is predicated on the assumption that parenterally administered eltopra zine stimulates 5-HTl receptors throughout the brain. The dose-dependent suppression of REM emphasizes the importance of endogenous serotonergic influences in controlling behavioral state and is consistent with the hypothesis that 5-HT neurons act to inhibit REM sleep but do not induce somnolence (Hobson and Stori ate 1986) . Suppression of PGO wave activity may be the result of serotonergic inhibition of the PGO wave trigger zone in the dorsolateral pons (Sakai 1980) . This increase in S sleep and concomitant increase in EEG synchrony may be explained by either nonserotoner gic processes (i. e., cholinergic antagonism) or by serotonergic modulation of thalamocortical or reticu lothalamic pathways, resulting in a functional deaffer- Delta I rf � �W�\ �/"ml ' entation of the cortex from thalamic influences (Hob son and Steriade 1986; Steriade et al. 1990b) . While increasing doses of eltoprazine increased S%, a signifIcant effect on delta wave counts was only seen at the highest (4 mg/kg) dose. For all other doses delta wave counts were close to control levels . This suggests that 4 mg/kg eltoprazine increases EEG synchrony far above control values, such that a rise in delta wave counts is also seen. However, this does not mean that eltoprazine has no influence on EEG synchrony at lower doses. The DAS used period-amplitude analysis to count all waves in the 1 to 4 Hz range as delta waves, regardless of amplitude. Qualitatively, we observed that lower doses of eltoprazine increase EEG synchrony and amplitude, along with S%. This qualitative change may not have been identifIed quantitatively by the DAS if the increased synchrony changed wave frequency from a high delta range (3 to 4 Hz) to a low range (1 to 2 Hz), such that the total number of counts per hour remained unchanged despite the increased number of epochs scored in an hour of S sleep. Spectral analysis would be useful in evaluating this issue.
Total time awake was unaffected by eltoprazine regardless of dose. This fmding contrasts with reported increases in time awake following administration of the reuptake blockers zimeldine and alaproclate (Ursin et al. 1989 ) and other studies reporting sleep-disruptive effects of serotonergic agents (Lucki and Frazer 1982) . The nonarousing effects of eltoprazine may be attribut able to the intrinsic properties of the drug itself. How ever, we propose an alternate explanation: 5-HTI receptors may be important in modulating the REM NREM ultradian cycle but less important in modulat ing sleep-wake control.
Dose-response results indicate that PGO wave generation is the most sensitive electrographic param eter measured with regard to eltoprazine, being sup pressed at doses unable to suppress REM. This sug gests that PGO activity is strongly modulated by serotonergic influences. In physiologically normal REM, PGO phasic activity is generated by spontaneous burst ing and discharge of PGO neurons located within the peribrachial pontine tegmentum (Sakai 1980) . Lesion ing of the raphe and administration of PCP A (Ruch Monachon et al. 1976a ), a blocker of 5-HT synthesis, are both reported to result in an increase in PGO waves. Serotonin agonists injected systemically are reported to result in a decrease of PGO frequency, indicating that suppressed in a dose-dependent manner (p < 0.001). Delta wave counts (middle) and EMG amplitude (bottom) demon strate a dose-dependent increase (p < 0.001). Typical wave band recordings of equal time calibration (8 seconds) for PGa, delta, and EMG activity (insets) are illustrated from saline con trol (left) and 4 mg/kg eltoprazine (right) experiments.
the activity of 5-HT neurons inhibits PGO wave gener ation (Ruch-Monachon et al. 1976b) . These fmdings to gether with our present results lead us to believe that 5-HT may now be confldently viewed as an inhibitory modulator of PGO activity. Furthermore, iontophoretic and raphe stimulation studies based on extracellular recordings in vivo have shown inhibitory effects of 5-HT on LGB neurons (Yoshida et al. 1984; Marks et al. 1987; Kayama et al. 1989 ). More recently, intracellular studies in vitro have shown that the response of thalamocorti cal relay LGB neurons to 5-HT is a slow depolarizing cation current, the response being blocked by methyser gide, a 5-HT1,2 antagonist (McCormick and Pape 1990). However, applications of the 5-HT1A agonist ipsapi rone or the partial agonist 8-hydroxy-dipropylamino tetralin were without effect (McCormick and Pape 1990) . PGO dose-related suppression by eltoprazine also sup ports the hypothesized PGO "gating" function (Simon et al. 1973; Trulson and Boys 1984) subserved by serotonergic neurons across behavioral states. There also may exist a "ceiling" dose for PGO suppression by eltoprazine of 2 mg/kg, indicating that higher doses saturate the system. The virtual total suppression of PGO activity at doses of 2 and 4 mg/kg eltoprazine com pared with the total suppression of REM only at the highest dose (4.0 mg/kg) suggests a possible differen tial sensitivity between PGO activity and other electro graphic features of REM to 5-HT inhibitory influences.
Since the computer program that counted PGO waves preferentially detects larger amplitude single spike type I waves over type II wave clusters (Mame lak et al. 1988) , the total number of PGO waves tabu lated actually underestimates the number of PGO waves that occurred. As REM% and PGO wave activ ity decreased with increasing doses of eltoprazine, the actual number of PGO waves decreased even more than was tabulated by the DAS, so that the actual dose de pendency of PGO activity is almost certainly more signifIcant than calculated.
We also observed a signifIcant dose-dependent in crease in EMG amplitude which may reflect an up regulation at the receptor level, such that increased lev els of 5-HT result in enhanced EMG tonus. This fmding is consistent with studies of 5-HT reuptake blockers (Sommerfelt and Ursin 1987 ) that typically demonstrate increased tonus associated with arousal, which we did not observe with eltoprazine. We suspect that circulat ing levels of eltoprazine result in a persistent inhibition of the pontine locus coeruleus alpha region (Sakai et al. 1981) , thus maintaining EMG tonus at higher levels during all phases of sleep than in physiologically nor mal sleep.
In summary, effects of eltoprazine administration demonstrate dose-dependent suppression of REM sleep and PGO activity, increases in S sleep, and no effect on waking. Eltoprazine shifts the balance between NEUROPSYCHOPHARMACOLOGY 1993-VOL. 8, NO. 1 REM and S sleep but does not change the balance of sleep and waking. Eltoprazine is thus of potential use as a tool for investigating serotonergic-cholinergic in teraction.
